Physician profile
Robert A Loera
NPI 1639287642
$11,239.50
in general payments reported to CMS, 2019-2025
46 companies · $1,328 in 2025
The $1,328 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,483 · 2020: $1,148 · 2021: $1,715 · 2022: $1,938 · 2023: $1,507 · 2024: $1,120 · 2025: $1,328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,954.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,634.36 | 2019-2022 | |
| Amgen INC. | $954.68 | 2020-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $941.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $932.96 | 2020-2025 | |
| Lilly USA, LLC | $771.06 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $757.92 | 2019-2025 | Tradjenta, Jardiance, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $726.55 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $644.93 | 2021-2024 | |
| Pfizer INC. | $588.07 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $455.89 | 2019-2024 | Vaxneuvance, Gardasil 9, Varivax |
| Esperion Therapeutics, INC. | $396.20 | 2020-2025 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $367.76 | 2019-2025 | Xifaxan |
| Amarin Pharma, INC. | $289.77 | 2019-2021 | |
| Glaxosmithkline, LLC. | $237.23 | 2019-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Astellas Pharma US INC | $134.14 | 2019-2021 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Loera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.